Epoprostenol sodium
Based on 1 publication(s) in Google Scholar
Epoprostenol sodium (Prostaglandin I2) sodium salt, the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH). Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation.
For research use only. We do not sell to patients.
- Purity: 98.03%
- CAS No.: 61849-14-7
- Formula: C20H31NaO5
- Molecular Weight:374.45
-
Storage:
-20°C, sealed storage, away from moisture
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Epoprostenol sodium
More
Customer Validation & Images
-
Cell Imaging/Staining
All Endogenous Metabolite Isoforms
More
Biological Activity
|
Human Endogenous Metabolite |
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 61849-14-7
-
Appearance Solid
-
Molecular Weight 374.45
-
Formula C20H31NaO5
-
Color White to yellow
-
SMILES
CCCCC[C@H](O)/C=C/[C@@H]1[C@@]([C@]2([H])C[C@H]1O)([H])C/C(O2)=C/CCCC(O[Na])=O
-
Synonyms
Prostaglandin I2 sodium salt; Prostacyclin sodium salt; Flolan
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2025 Oct 2;16(1):8779. PMID: 41038808
Epoprostenol sodium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Oct 2;16(1):8779. [Abstract]
Transmission electron microscopy and quantitative analysis of platelet morphology and platelet-derived microparticles in washed platelets isolated using Epoprostenol sodium (0.1 μg/mL; including a 10-min centrifugation step during platelet Obtain) in nMG, HC, and MMS groups.
Solvent & Solubility
H2O : 25 mg/mL (66.76 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Provencher S, et al.Quality of life, safety and efficacy profile of thermostable flolan in pulmonary arterialhypertension. PLoS One. 2015 Mar 20;10(3):e0120657. [Content Brief]
[2]. Lambert O, et al. Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted[J]. Drug Design, Development and Therapy, 2012: 61-70. [Content Brief]
[3]. Akagi S, et al. Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension[J]. International journal of cardiology, 2013, 165(3): 499-505. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.6706 mL | 13.3529 mL | 26.7058 mL | 66.7646 mL |
| 5 mM | 0.5341 mL | 2.6706 mL | 5.3412 mL | 13.3529 mL | |
| 10 mM | 0.2671 mL | 1.3353 mL | 2.6706 mL | 6.6765 mL | |
| 15 mM | 0.1780 mL | 0.8902 mL | 1.7804 mL | 4.4510 mL | |
| 20 mM | 0.1335 mL | 0.6676 mL | 1.3353 mL | 3.3382 mL | |
| 25 mM | 0.1068 mL | 0.5341 mL | 1.0682 mL | 2.6706 mL | |
| 30 mM | 0.0890 mL | 0.4451 mL | 0.8902 mL | 2.2255 mL | |
| 40 mM | 0.0668 mL | 0.3338 mL | 0.6676 mL | 1.6691 mL | |
| 50 mM | 0.0534 mL | 0.2671 mL | 0.5341 mL | 1.3353 mL | |
| 60 mM | 0.0445 mL | 0.2225 mL | 0.4451 mL | 1.1127 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Epoprostenol sodium Related Classifications
HY-A0126A Related Classifications
Powered by Bioz